Who we are and what we do

We are a team of professionals with long time experience of in-vivo pharmacology and toxicology. We assist pharmaceutical companies in their endeavours to find cures for diseases for which there are no effective treatments today and those who are working to improve the effectiveness of discovered drugs.

How we work

Together with the customer we develop a project plan. Depending on the challenge Adlego Biomedical either runs projects solitary or puts together a group of experts from our network to manage complex projects. Therefore, we can be cost effective and produce with the highest quality a variety of studies from standard DMPK studies to demanding effect studies and large toxicity studies.

Why are preclinical studies needed?

To enter into clinical trials pharmaceutical companies need to demonstrate to regulatory agencies that a new drug is effective and relatively safe to administer to humans. Information about interactions between a new drug and a living organism is obtained with use of preclinical methods.

Focus

Our main focus is to establish long-term collaboration with drug developing companies that are early in their development of new candidate drugs. With this approach we establish a relationship that is fruitful for both parties when disease models need to be developed to show proof-of-concept, and when DMPK and toxicity data are gathered. Since we are working with experts within the various fields of drug development and document all studies according to GLP the customer is guaranteed top quality reports, which fulfil the requirements of regulatory bodies. 79334397-258x120

Case

Although we have been working with many models of cancer we continue to get requests for models we have not used before. Before we use a new model in proof-of-concept studies we validate it to obtain information about growth rate and to show that the tumour is sensitive to current therapies. We commonly also use histological techniques to further analyze the effect of therapies. Here is an example from the validation of the ACHN tumour model: Bild31

Latest News

Kanceras HDAC6-projekt tilldelas anslag från Vinnova

Pressmeddelande Stockholm 2015-06-12 Kanceras HDAC6-projekt tilldelas anslag från Vinnova Kancera har av Sveriges innovationsmyndighet VINNOVA tilldelats ett anslag om totalt 2,000,000 kronor riktat till projekt som kan utvecklas till nya starka innovationer....

read more

The true value of a good partnership!

  Urban Hoglund met Ari Tolonen, who is the CEO of Admescope, at the Nordic Life Science Day event in 2012. Admescope is a Finnish CRO that provides Bioanalytical services as part of their broad ADME-Tox service offering. The value of finding the right...

read more

Successful LÄKEMEDELSEVENTET 2015!

On Wednesday 22nd April in the afternoon, Adlego Biomedical were part of the Läkemedelseventet 2015. About 50 delegates were present who enjoyed listening to presentations about alternative and innovative solutions to advance the development of potential new...

read more

Latest Publications

Mass spectrometry of macromolecules

Data on the use of accelerator mass spectrometry (AMS) in conjunction with in vivo studies of macromolecular drugs are scarce. The present study shows the versatility of this technique when investigating the pharmacokinetics (PK) of a macromolecular drug candidate, a...

read more

Multigene HIV vaccine

It is likely that gene-based vaccines will enter the human vaccine area soon. A few veterinary vaccines employing this concept have already been licensed, and a multitude of clinical trials against infectious diseases or different forms of cancer are ongoing. Highly...

read more

In vivo electroporation

The mechanisms by which in vivo electroporation (EP) improves the potency of i.m. DNA vaccination were characterized by using the hepatitis C virus nonstructural (NS) 3/4A gene. Following a standard i.m. injection of DNA with or without in vivo EP, plasmid levels...

read more